Previous 10 | Next 10 |
home / stock / lbtsf / lbtsf news
Almirall’s Full-Year 2023 Results Company revenue growth driven by the strong performance of the European Dermatology business (+17% year-on-year) based on key growth divers and new launches: Ilumetri ® growing sales at 33.5% year-on-year; Klisyri ® strong sales g...
The phase I study will evaluate the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALM223 ALM223 has the potential to rebalance the immune system in several autoimmune diseases 1,2 Almirall S.A. (BME: ALM ) , a global pharmaceutical compa...
The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront a...
Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity, selectively inhibiting its downstream signalling 1-4 Following the European Commission approval, Germany is the first country where lebrikizumab will be available for prescription Lebrikizumab demons...
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases Almirall S.A. (BME: ALM ) , a global biopharmaceutical company focused on medical dermatology, and Absci Corpo...
2023-11-11 00:59:06 ET Almirall, S.A. (LBTSF) Q3 2023 Earnings Conference Call November 9, 2023, 4:00 AM ET Company Participants Pablo Divasson - Director, Investor Relations and Corporate Communications Carlos Gallardo - Chairman and CEO Mike McClellan - Chief F...
Almirall achieves Net Sales growth of 6.4%, driven by strong European dermatology performance Almirall's European Dermatology business continued to be the driving force behind Almirall's strong performance in the first nine months of 2023, with a growth rate of 15.9% underpinned by the su...
First readout of two-year data from long-term extension study 43rd Annual Fall Clinical Dermatology Conference Almirall S.A. (BME:ALM ), a global biopharmaceutical company focused on medical dermatology, today announced results from the long-term extension study ...
These primary data of the ADvantage study were presented today at EADV Congress A total of 18 lebrikizumab abstracts were disclosed at EADV, including new data on the depth of response at Week 52 and long-term clinically meaningful response Lebrikizumab also demonstrated improveme...
Interim data from the POSITIVE study, presented at the EADV, revealed that tildrakizumab not only significantly improved patients’ wellbeing after 16 weeks, which was maintained up to week 28 1 but also had a positive impact on the wellbeing of their relatives after 28 weeks 2 ...
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...
Almirall presented the interim Week 52 results of the POSITIVE clinical study at the IFPA Conference 2024, showing the benefits of the effective treatment with Ilumetri (tildrakizumab) in patients with moderate to severe psoriasis achieving improvement of physical symptoms and overall wellbeing. ...
Positive trajectory with Net Sales increase by 6.6% to a total of €247.4 MM, EBITDA increase of 1.4% YoY to a total of €52.5 MM driven by higher overall sales Performance driven by biologics as key growth engines, with Ilumetri ® showing 30% increase in sales vs Q1 ...